CMRX Chimerix, Inc.

6.19
+0  (1%)
Previous Close 6.15
Open 6.16
Price To book 1.04
Market Cap 288.18M
Shares 46,555,000
Volume 332,261
Short Ratio 7.68
Av. Daily Volume 476,105

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b to be initiated late 2017.
Brincidofovir
BK virus
Phase 2b to be initiated late 2017.
Brincidofovir
Cytomegalovirus (CMV)
Phase 3 interim analysis released May 2016. Final data released February 22, 2017.
Brincidofovir - Advise trial
Adenovirus Infection
Phase 3 discontinued following poor data from SUPPRESS trial
Brincidofovir - SURPASS
Cytomegalovirus (CMV) infection
Phase 3 endpoints not met December 2015
Brincidofovir - SUPPRESS
Cytomegalovirus (CMV) infection following an allogeneic hematopoietic stem cell transplant (HSCT)
Phase 3 discontinued following poor data from SUPPRESS trial
Brincidofovir - SUSTAIN
Cytomegalovirus (CMV) infection

Latest News

  1. Chimerix, Inc. :CMRX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
  2. Chimerix, Inc. :CMRX-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
  3. CHIMERIX INC Financials
  4. Edited Transcript of CMRX earnings conference call or presentation 2-Mar-17 1:30pm GMT
  5. CHIMERIX INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
  6. Chimerix reports 4Q loss
  7. Chimerix reports 4Q loss
  8. Q4 2016 Chimerix Inc Earnings Release - Before Market Open
  9. Chimerix Announces Fourth Quarter and Full Year 2016 Financial Results
  10. Chimerix to Present at Cowen and Company 37th Annual Health Care Conference
  11. Chimerix to Announce Fourth Quarter and Full Year 2016 Financial Results on March 2, 2017
  12. Chimerix Announces Final Data from AdVise Trial of Brincidofovir at BMT Tandem Meetings
  13. 5 Breakout Stocks for Superior Returns
  14. Will Chimerix (CMRX) Continue to Surge Higher?
  15. Falling Earnings Estimates Signal Weakness Ahead for Agios Pharmaceuticals (AGIO)
  16. Chimerix Announces Preliminary Data from Ongoing Phase 1 Dose Escalation Study of Intravenous Brincidofovir in Healthy Subjects
  17. CHIMERIX INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  18. Chimerix Announces Preliminary Data from Ongoing Phase 1 Dose Escalation Study of Intravenous Brincidofovir in Healthy Subjects
  19. Chimerix Appoints Randall Lanier, PhD as Chief Science Officer, and Roy W. Ware, PhD, MBA as Chief Manufacturing and Technology Officer
  20. Chimerix Appoints Randall Lanier, PhD as Chief Science Officer, and Roy W. Ware, PhD, MBA as Chief Manufacturing and Technology Officer
  21. Chimerix to Present at the 35th Annual J.P. Morgan Healthcare Conference
  22. Should You Buy Beigene Ltd (ADR) (BGNE)?
  23. Here is What Hedge Funds Think About Chimerix Inc (CMRX)
  24. ETFs with exposure to Chimerix, Inc. : December 5, 2016
  25. ETF’s with exposure to Chimerix, Inc. : November 10, 2016
  26. Chimerix to Present at Upcoming Investor Conferences
  27. Chimerix Announces Third Quarter 2016 Financial Results
  28. Chimerix to Announce Third Quarter 2016 Financial Results on November 7, 2016
  29. Chimerix Announces Presentation at IDWeek™ of Detailed 24-Week Results from AdVise Trial of Brincidofovir for the Treatment of Adenovirus Infection in Allogeneic Hematopoietic Cell Transplant Recipients
  30. Chimerix Announces Second Quarter 2016 Financial Results
  31. Chimerix to Announce Second Quarter 2016 Financial Results on August 8, 2016
  32. Chimerix to Participate in Panel on North Carolina's Role in Biodefense Preparation at Medical, Biomedical and Biodefense Symposium
  33. Chimerix Announces Top-Line Interim AdVise Data and First Quarter 2016 Financial Results
  34. Chimerix to Announce First Quarter 2016 Financial Results on May 9, 2016